Sarepta Therapeutics could meet its revised outlook following a recent cut in its revenue guidance for Elevidys, Oppenheimer said in a note.
https://www.marketscreener.com/quote/stock/SAREPTA-THERAPEUTICS-INC-11204214/news/Sarepta-Likely-to-Meet-Revised-Guidance-Oppenheimer-Says-50193926/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.